Sofinnova Partners closes its €650M flagship fund to back early-stage biotech and medtech startups across Europe and North America.
Contentlockr
Paris-based Sofinnova Partners, a European venture capital firm in life sciences, announced the close of its latest flagship fund—Sofinnova Capital XI, at €650M, exceeding its initial target.
The VC‘s latest fund is backed by a global base of blue-chip institutional investors, including sovereign wealth funds, leading pharmaceutical companies and other corporates, as well as insurance companies, foundations, and family offices.
Investors come from Europe, North America, Asia, and the Middle East. Most are returning partners, but there are also many new, high-profile investors.
Focuses on biopharmaceutical and medical technology
Sofinnova Capital XI is focused on investing in innovative biopharmaceutical and medical technology companies that meet critical clinical needs.
The fund benefits from a strong team of experienced partners: Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi.
Sofinnova Capital XI is currently investing and has already supported several companies.
The fund aims to back early-stage biotech and medtech ventures in Europe and North America, participating in both initial and follow-up funding rounds.
Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, says, “This fundraising marks a pivotal moment for Sofinnova. It gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach. We’re excited to continue backing visionary entrepreneurs and advancing the next wave of breakthroughs in science and medicine to bring them to patients worldwide.”
“Achieving this milestone in today’s volatile fundraising environment speaks to the strength of our model and the confidence our investors continue to place in us,” says Papiernik.
Sofinnova Partners: Specialising in healthcare and sustainability
Founded in 1972, Sofinnova Partners is a venture capital firm in life sciences, specialising in healthcare and sustainability. At present, the VC firm manages over €4B in assets under management.
The French VC is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.
Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with scientific, medical and business expertise.
The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
